Randomized phase II study of two different schedules of gemcitabine and oral S-1 in <font color="blue">chemo_4</font> <font color="blue">-_4</font> <font color="blue">naïve_4</font> <font color="blue">patients_4</font> <font color="blue">with_4</font> <font color="blue">advanced_4</font> <font color="blue">non_4</font> <font color="blue">-_4</font> <font color="blue">small_4</font> <font color="blue">cell_4</font> <font color="blue">lung_4</font> <font color="blue">cancer_4</font> <font color="blue">._4</font> 
<br>
<br> INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in <font color="blue">chemo_3</font> <font color="blue">-_3</font> <font color="blue">naïve_3</font> <font color="blue">non_3</font> <font color="blue">-_3</font> <font color="blue">small_3</font> <font color="blue">cell_3</font> <font color="blue">lung_3</font> <font color="blue">cancer_3</font> <font color="blue">patients_3</font> <font color="blue">._3</font> <font color="blue">
<br>_1</font> METHODS <font color="blue">Patients_5</font> <font color="blue">with_5</font> <font color="blue">chemo_5</font> <font color="blue">-_5</font> <font color="blue">naïve_5</font> <font color="blue">stage_5</font> <font color="blue">IIIB_5</font> <font color="blue">/_5</font> <font color="blue">IV_5</font> <font color="blue">non_5</font> <font color="blue">-_5</font> <font color="blue">small_5</font> <font color="blue">cell_5</font> <font color="blue">lung_5</font> <font color="blue">cancer_5</font> <font color="blue">were_2</font> <font color="blue">randomized_2</font> <font color="blue">into_2</font> <font color="blue">two_2</font> <font color="blue">treatment_2</font> <font color="blue">arms_2</font> <font color="blue">._2</font> <font color="blue">Patients_1</font> <font color="blue">were_1</font> <font color="blue">given_1</font> <font color="blue">oral_1</font> <font color="blue">S-1_1</font> <font color="blue">(_1</font> <font color="blue">60_1</font> <font color="blue">mg_1</font> <font color="blue">/_1</font> <font color="blue">m_1</font> <font color="blue">/_1</font> <font color="blue">d_1</font> <font color="blue">,_1</font> <font color="blue">twice_1</font> <font color="blue">a_1</font> <font color="blue">day_1</font> <font color="blue">)_1</font> <font color="blue">from_1</font> <font color="blue">days_1</font> <font color="blue">1_1</font> <font color="blue">to_1</font> <font color="blue">14_1</font> <font color="blue">with_1</font> <font color="blue">gemcitabine_1</font> <font color="blue">(_1</font> <font color="blue">1000_1</font> <font color="blue">mg_1</font> <font color="blue">/_1</font> <font color="blue">m_1</font> <font color="blue">/_1</font> <font color="blue">d_1</font> <font color="blue">)_1</font> <font color="blue">on_1</font> <font color="blue">days_1</font> <font color="blue">1_1</font> <font color="blue">and_1</font> <font color="blue">8_1</font> <font color="blue">(_1</font> <font color="blue">arm_1</font> <font color="blue">A_1</font> <font color="blue">)_1</font> <font color="blue">or_1</font> <font color="blue">on_1</font> <font color="blue">days_1</font> <font color="blue">8_1</font> <font color="blue">and_1</font> <font color="blue">15_1</font> <font color="blue">(_1</font> <font color="blue">arm_1</font> <font color="blue">B_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> <font color="blue">This_1</font> <font color="blue">cycle_1</font> <font color="blue">was_1</font> <font color="blue">repeated_1</font> <font color="blue">every_1</font> <font color="blue">21_1</font> <font color="blue">days_1</font> <font color="blue">._1</font> 
<br> RESULTS <font color="blue">A_3</font> <font color="blue">total_3</font> <font color="blue">of_3</font> <font color="blue">80_4</font> <font color="blue">patients_4</font> <font color="blue">were_2</font> <font color="blue">entered_2</font> <font color="blue">in_2</font> <font color="blue">this_2</font> <font color="blue">trial_2</font> <font color="blue">._2</font> The primary end point of this study was response rate . The response rates of arm A and arm B were 22.0 and 28.9% , respectively ( p = 0.606 ) . Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm B. Median time to progression in arm A was 4.1 months and 5.5 months in arm B. Median survival time in arm A and arm B was 15.5 months and 18.8 months , respectively . The toxicity profile was relatively mild and did not differ very much between two arms . 
<br> CONCLUSION The combination of gemcitabine and S-1 was determined to be feasible and effective for <font color="blue">advanced_1</font> <font color="blue">non_1</font> <font color="blue">-_1</font> <font color="blue">small_1</font> <font color="blue">cell_1</font> <font color="blue">lung_1</font> <font color="blue">cancer_1</font> <font color="blue">._1</font> We selected arm B for further studies because of its higher response rate and survival data .